ArticleFrontiers in pharmacology2025

Pharmacovigilance study on neurological adverse reactions of proteasome inhibitors in the FDA adverse event reporting system.

Shuyue Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.